ViaDerma, Inc. Begins Consumer Testing on its Topical Antibiotic in the Philippines Due to Country Wide Interest from Distributors as it Eyes Huge Market for Several New Follow-on Products with Registration Numbers from the FDA Soon to Follow
LOS ANGELES, CA–(Marketwired – June 15, 2017) – ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has commenced “Consumer Test Studies” of its tetracycline based topical antibiotic in the Philippines. The product has been well received by Doctors and Distributors throughout the country. The Distributors are also interested in ViaDerma’s six follow-on products which are expecting FDA registration numbers throughout the rest of 2017.
The Philippines is well acquainted with pharmaceutical manufacturing for companies such as GlaxoSmithKline, Novartis and Sanofi, which are among the largest foreign pharmaceutical companies doing business in the Philippines. Among domestic drug companies, United Laboratories, Pascual Laboratories, GC International and Natrapharm are the largest. ViaDerma’s topical antibiotic is now ready for sale. The antibiotics market is expected to reach USD $57.0 billion by 2024, according to the new report by Grand View Research, Inc. Rising prevalence of infectious diseases especially in developing regions such as Asia Pacific and MEA is anticipated to contribute towards market growth. ViaDerma sees the environment for its product line as a natural fit as the generics and over the counter segments have become increasingly important in the Philippines. ViaDerma, Inc. has completed the quality control and approved labeling for the product in the USA and will begin distribution of the drug later this month.
The Company’s President, Dr. Christopher Otiko said, “We have seen increased interest in our products due to the need in this part of the world. The closer we are to distribution it seems we are pleasantly surprised by Distributors’ inquiries for the medication. Our product manufacturer will be able to manufacture most of our products and we look forward to building a lasting relationship to deliver high quality pharmaceuticals to our distributors.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s products use an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBDs and THC with the delivery system was filed in 2017. The use of CBDs is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
Dr. Christopher Otiko
Chief Executive Officer